Research Overview

Retatrutide is a next-generation multi-agonist peptide that engages GIP, GLP-1 and glucagon receptors simultaneously. It is used in laboratory and preclinical models to study integrated control of body weight, glucose homeostasis and whole-body energy balance, without implying any therapeutic or clinical use.

Primary Research Areas

• Triple GIP/GLP-1/glucagon receptor agonism: Mechanistic studies dissecting receptor pharmacology, biased signaling and downstream pathways triggered by combined incretin and glucagon receptor activation.
• Obesity & body-weight regulation models: In vivo models exploring changes in body weight, adiposity, food intake and energy expenditure under Retatrutide-driven multi-agonist signaling.
• Glycemic control & metabolic health: Research focused on glucose tolerance, insulin dynamics, hepatic glucose output and broader metabolic homeostasis in preclinical systems.